BioCentury
ARTICLE | Financial News

Jounce raises $56M in series B round

April 24, 2015 1:50 AM UTC

Cancer company Jounce Therapeutics Inc. (Cambridge, Mass.) raised $56 million in a series B round from Wellington Management, Redmile Group, Nextech Invest, Pharmstandard International, Cormorant Asset Management, Omega Funds, Casdin Capital, Foresite Capital and an undisclosed public investment fund.

Jounce plans to start clinical testing next year of its inducible T cell co-stimulator (ICOS) agonist antibody. ...